{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T17:51:47Z","timestamp":1776275507079,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.ijantimicag.2022.106664","type":"journal-article","created":{"date-parts":[[2022,8,21]],"date-time":"2022-08-21T09:38:00Z","timestamp":1661074680000},"page":"106664","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Comparative efficacy of dalbavancin alone and with rifampicin against in vitro biofilms in a pharmacodynamic model with methicillin-resistant Staphylococcus aureus"],"prefix":"10.1016","volume":"60","author":[{"given":"Cristina","family":"El Haj","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9891-1766","authenticated-orcid":false,"given":"Eva","family":"Benavent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanik","family":"Sierra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Soldevila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5511-074X","authenticated-orcid":false,"given":"Raul","family":"Rigo-Bonnin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Torrej\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Gomez-Junyent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irantzu","family":"Rossell\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5776-8422","authenticated-orcid":false,"given":"Oscar","family":"Murillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2022.106664_bib0001","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/sj.clpt.6100247","article-title":"The challenge of treating biofilm-associated bacterial infections","volume":"82","author":"del Pozo","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2022.106664_bib0002","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/cis803","article-title":"Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America","volume":"56","author":"Osmon","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106664_bib0003","unstructured":"European Medicines Agency (EMA). Xydalba summary of product characteristics 2015. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2015\/20150219130765\/anx_130765_en.pdf."},{"key":"10.1016\/j.ijantimicag.2022.106664_bib0004","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once-weekly dalbavancin versus daily conventional therapy for skin infection","volume":"370","author":"Boucher","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2022.106664_bib0005","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1093\/jac\/dky235","article-title":"Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015\u201316","volume":"73","author":"Pfaller","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106664_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2020.115195","article-title":"Update on the in vitro activity of dalbavancin against indicated species (Staphylococcus aureus, Enterococcus faecalis, \u03b2-hemolytic streptococci, and Streptococcus anginosus group) collected from United States hospitals in 2017-2019","volume":"99","author":"Sader","year":"2021","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106664_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2019.114901","article-title":"In vitro time-kill kinetics of dalbavancin against Staphylococcus spp. biofilms over prolonged exposure times","volume":"96","author":"Di Pilato","year":"2020","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106664_bib0008","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.diagmicrobio.2016.05.009","article-title":"In vitro activity of dalbavancin against biofilms of staphylococci isolated from prosthetic joint infections","volume":"85","author":"Fern\u00e1ndez","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106664_bib0009","doi-asserted-by":"crossref","first-page":"5688","DOI":"10.1128\/AAC.01251-16","article-title":"Evaluation of antibiotics active against methicillin-resistant Staphylococcus aureus based on activity in an established biofilm","volume":"60","author":"Meeker","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106664_bib0010","doi-asserted-by":"crossref","first-page":"4329","DOI":"10.1128\/AAC.00455-10","article-title":"Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm","volume":"54","author":"Parra-Ruiz","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106664_bib0011","first-page":"51","article-title":"Evaluation of linezolid or trimethoprim\/sulfamethoxazole in combination with rifampicin as alternative oral treatments based on an in vitro pharmacodynamic model of staphylococcal biofilm","author":"El Haj","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2022.106664_bib0012","unstructured":"Patel JR, Cockerill FR, Bradford PA, Eliopoulos GM, Hindler JA, Jenkins SG, et\u00a0al. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard\u2014Tenth Edition M07-A10 2015;35."},{"key":"10.1016\/j.ijantimicag.2022.106664_bib0013","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1128\/JCM.37.6.1771-1776.1999","article-title":"The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms","volume":"37","author":"Ceri","year":"1999","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2022.106664_bib0014","unstructured":"Clinical and Laboratory Standards Institute. Methods for determining bactericidal activity of antimicrobial agents; approved guideline M26-A. vol. 19. 1999."},{"key":"10.1016\/j.ijantimicag.2022.106664_bib0015","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1128\/AAC.00523-06","article-title":"Efficacy of high doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus","volume":"50","author":"Murillo","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106664_bib0016","doi-asserted-by":"crossref","unstructured":"Grayson ML, Crowe SM, McCarthy JS, Mills J, Mouton JW, Norrby SR, et\u00a0al. Kucers\u2019 The Use of Antibiotics Sixth Edition: A Clinical Review of Antibacterial, Antifungal and Antiviral Drugs. sixth edit. 2011. doi:10.1093\/jac\/dkr468.","DOI":"10.1093\/jac\/dkr468"},{"key":"10.1016\/j.ijantimicag.2022.106664_bib0017","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01743-18","article-title":"Dalbavancin alone and in combination with ceftaroline against four different phenotypes of Staphylococcus aureus in a Simulated pharmacodynamic\/pharmacokinetic model","volume":"63","author":"Kebriaei","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl A","key":"10.1016\/j.ijantimicag.2022.106664_bib0018","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/jac\/15.suppl_A.125","article-title":"In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives","volume":"15","author":"Blaser","year":"1985","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106664_bib0019","unstructured":"European Society of Clinical Microbiology and Infectious Diseases. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters Version 11.0 2021. https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_11.0_Breakpoint_Tables.pdf."},{"key":"10.1016\/j.ijantimicag.2022.106664_bib0020","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1128\/AAC.00169-16","article-title":"Comparative in vitro activities of oritavancin, dalbavancin, and vancomycin against methicillin-resistant Staphylococcus aureus isolates in a nondividing state","volume":"60","author":"Belley","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106664_bib0021","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ijantimicag.2005.12.015","article-title":"Evaluation of dalbavancin in combination with nine antimicrobial agents to detect enhanced or antagonistic interactions","volume":"27","author":"Johnson","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2022.106664_bib0022","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ijantimicag.2013.05.019","article-title":"Activity of dalbavancin, alone and in combination with rifampicin, against meticillin-resistant Staphylococcus aureus in a foreign-body infection model","volume":"42","author":"Baldoni","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2022.106664_bib0023","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/jac\/dkv357","article-title":"Efficacy of dalbavancin in the treatment of MRSA rat sternal osteomyelitis with mediastinitis","volume":"71","author":"Barnea","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106664_bib0024","doi-asserted-by":"crossref","first-page":"9661","DOI":"10.1038\/s41598-018-28006-8","article-title":"Dalbavancin for treatment of implant-related methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model","volume":"8","author":"Kussmann","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2022.106664_bib0025","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/clinids\/20.2.320","article-title":"Pyogenic vertebral osteomyelitis: Analysis of 20 cases and review","volume":"20","author":"Torda","year":"1995","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106664_bib0026","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/cid\/ciw100","article-title":"Editorial commentary: Pyogenic vertebral osteomyelitis and antimicrobial therapy: It's not just the length, but also the choice","volume":"62","author":"Murillo","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106664_bib0027","doi-asserted-by":"crossref","first-page":"ofy331","DOI":"10.1093\/ofid\/ofy331","article-title":"Dalbavancin for the treatment of osteomyelitis in adult patients: A randomized clinical trial of efficacy and safety","volume":"6","author":"Rappo","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106664_bib0028","first-page":"835","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Heal Pharm AJHP Off J Am Soc Heal Pharm"},{"key":"10.1016\/j.ijantimicag.2022.106664_bib0029","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1128\/AAC.38.5.931","article-title":"Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model","volume":"38","author":"Mouton","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106664_bib0030","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1128\/AAC.41.6.1293","article-title":"In vitro activities of ciprofloxacin and rifampin alone and in combination against growing and nongrowing strains of methicillin-susceptible and methicillin-resistant Staphylococcus aureus","volume":"41","author":"Bahl","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106664_bib0031","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s40121-014-0055-5","article-title":"Evaluation of high-dose daptomycin versus vancomycin alone or combined with clarithromycin or rifampin against Staphylococcus aureus and S. epidermidis in a novel in vitro PK\/PD model of bacterial biofilm","volume":"4","author":"Hall Snyder","year":"2014","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.ijantimicag.2022.106664_bib0032","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ijantimicag.2017.11.008","article-title":"Dalbavancin in the treatment of different gram-positive infections: a real-life experience","volume":"51","author":"Bouza","year":"2018","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl 3","key":"10.1016\/j.ijantimicag.2022.106664_bib0033","doi-asserted-by":"crossref","first-page":"S507","DOI":"10.1093\/clinids\/5.Supplement_3.S507","article-title":"Emergence of rifampin-resistant strains of Staphylococcus aureus during combination therapy with vancomycin and rifampin: a report of two cases","volume":"5","author":"Simon","year":"1983","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106664_bib0034","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/jac\/15.2.201","article-title":"Differences in ability of cell-wall antibiotics to suppress emergence of rifampicin resistance in Staphyloccocus aureus","volume":"15","author":"Eng","year":"1985","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106664_bib0035","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3109\/00365548.2012.663931","article-title":"Decreased serum linezolid concentrations in two patients receiving linezolid and rifampicin due to bone infections","volume":"44","author":"Hoyo","year":"2012","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106664_bib0036","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1093\/jac\/dkq281","article-title":"Tolerability of prolonged linezolid therapy in bone and joint infection: protective effect of rifampicin on the occurrence of anaemia?","volume":"65","author":"Legout","year":"2010","journal-title":"J Antimicrob Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857922001844?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857922001844?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:43:51Z","timestamp":1760377431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857922001844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0924857922001844"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106664","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative efficacy of dalbavancin alone and with rifampicin against in vitro biofilms in a pharmacodynamic model with methicillin-resistant Staphylococcus aureus","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106664","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106664"}}